Cargando…
GLP-1 based therapies and disease course of inflammatory bowel disease
BACKGROUND: The disease course of inflammatory bowel disease (IBD) following treatment with glucagon-like peptide (GLP)-1 based therapies is unclear. The aim of this study was to examine the disease course of IBD in patients treated with GLP-1 based therapies compared with treatment with other antid...
Autores principales: | Villumsen, Marie, Schelde, Astrid Blicher, Jimenez-Solem, Espen, Jess, Tine, Allin, Kristine Højgaard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343256/ https://www.ncbi.nlm.nih.gov/pubmed/34386751 http://dx.doi.org/10.1016/j.eclinm.2021.100979 |
Ejemplares similares
-
The Risk of Type 2 Diabetes in Patients With Inflammatory Bowel Disease After Bowel Resections: A Nationwide Cohort Study
por: Allin, Kristine H., et al.
Publicado: (2022) -
Characterizing the pre-clinical phase of inflammatory bowel disease
por: Vestergaard, Marie Vibeke, et al.
Publicado: (2023) -
Risk of Cervical Cancer in Inflammatory Bowel Disease: A Meta-Analysis of Population-Based Studies
por: Mann, Simran, et al.
Publicado: (2022) -
Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases
por: Singh, Siddharth, et al.
Publicado: (2022) -
Clinical procedures used to diagnose inflammatory bowel disease: real-world evidence from a Danish nationwide population-based study
por: Rasmussen, Nathalie Fogh, et al.
Publicado: (2022)